News Conference News TCT 2019 AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups Todd Neale September 26, 2019
News Daily News DOACs Good for Secondary Prevention in Older A-fib Patients, Real-world Numbers Affirm Todd Neale July 23, 2019
News Conference News ACC 2019 AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI Caitlin E. Cox March 17, 2019
News Conference News ISC 2019 Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects Todd Neale February 13, 2019
News Conference News AHA 2018 Complications Following TAVR Are Going Down, US Data Show Yael L. Maxwell November 20, 2018
News Conference News ACC 2018 Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4 Todd Neale March 13, 2018
News Conference News ISC 2018 Experts Debate: Is It ‘Nuts’ to Restart Anticoagulation After Lobar ICH? Todd Neale January 30, 2018
News Daily News No Anticoagulation Benefit, High Bleeding Risk Seen in Patients With Secondary A-fib Michael O'Riordan September 29, 2017
News Daily News Rivaroxaban, Warfarin Provide Similar Results Early After Mild Strokes Related to A-fib Todd Neale September 14, 2017
News Daily News Do NOACs Carry a Higher Risk of Acute MI? New Study Reopens Old Questions Todd Neale March 28, 2017
News Daily News More A-fib, No Drop in Stroke or Death With Surgical Left Atrial Appendage Exclusion Todd Neale December 05, 2016
News Conference News AHA 2016 Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results Todd Neale November 15, 2016
News Daily News Low-Dose NOACs Top Warfarin in Asian Patients in Everyday Practice, Retrospective Study Suggests Todd Neale September 26, 2016
News Daily News Observational Study Supports Longer-Term Monitoring for A-fib After Cryptogenic Stroke Todd Neale April 22, 2016